logo-loader

Vyant Bio forges partnership with MASORI Therapeutics to pursue co-development partnerships with pharma companies

Last updated: 10:08 19 Oct 2021 EDT, First published: 10:06 19 Oct 2021 EDT

Vyant Bio - Vyant Bio forges partnership with MASORI Therapeutics to pursue co-development partnerships with pharma companies
'Partnerships are central to scientific advancement, and for patients with CNS and oncology diseases, time is of the essence to uncover new treatments as quickly as possible,' said Vyant Bio CEO Jay Roberts

Vyant Bio (NASDAQ:VYNT) Inc. has announced a new partnership with MASORI Therapeutics, a company focused on the pharmaceutical industry and applying artificial intelligence to achieve competitive advantage through the creation of innovative market solutions.

Under the agreement, the two companies will pursue co-development and out-licensing partnerships with pharmaceutical and biotechnology companies.

MASORI Therapeutics combines healthcare and digital expertise that enables life sciences companies to leverage artificial intelligence (AI), machine-learning, and virtual reality to achieve brand growth and better analysis, targeting, and execution.

READ: Vyant Bio and Cyclica in a strategic collaboration to identify compounds to treat CDKL5 Deficiency Disorder

The company’s work with Vyant Bio (NASDAQ:VYNT) will initially focus on Japan and will center on providing key insights into the application and intersection of their technologies to accelerate partnership-based therapeutic discovery and development.

“I am inspired by Vyant Bio’s commitment to innovation and the discovery of cures for intractable diseases,” MASORI Therapeutics Executive Chairman CEO Dane Hallberg said in a statement. “Vyant Bio embodies the tenets of MASORI Therapeutics, and we look forward to helping both companies drive and advance the development of new therapies that have the potential to make the greatest impact on patients.”

Cherry Hill, New Jersey-based Vyant Bio couples highly functional, complex in vitro human-based organoid platforms with advanced analytics and in vivo preclinical and regulatory expertise to bring the most promising compounds through the discovery pipeline. It incorporates patient biology early in the discovery process to identify, validate, and de-risk new targets and compounds prior to clinical trials.

“Partnerships are central to scientific advancement, and for patients with CNS and oncology diseases, time is of the essence to uncover new treatments as quickly as possible,” said Vyant Bio CEO Jay Roberts. “Our relationship with MASORI Therapeutics will identify and drive drug development partnerships that leverage our capabilities to accelerate the discovery and delivery of such treatments.”

Contact the author Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

5 hours, 12 minutes ago